Antiangiogenic therapies targeting specific endothelial cell markers are promising approaches for the treatment of cancer. One of the targets is endoglin, involved in cellular proliferation, differentiation and migration. We already demonstrated that endoglin silencing with siRNA has antitumor effect. To prolong the effect, we constructed two plasmid encoding shRNA against endoglin; one with constitutive promoter (CON) and the other with tissue specific promoter for endothelin-1 (TS) to increase specificity for endothelial cells, in order to compare theirs effectiveness. We proved that both gene electrotransfers of plasmids against endoglin had good and comparable antitumor effect, confirming the future potential of using TS plasmid, as it proves to be more specific and safer than CON plasmid.
F.18 Transfer of new know-how to direct users (seminars, fora, conferences)
COBISS.SI-ID: 1867387